

Nathan A Beutler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8732187/nathan-a-beutler-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

2,123
citations

15
h-index

32
g-index

32
ext. papers

3,098
ext. citations

17.5
avg, IF

4.49
L-index

#	Paper	IF	Citations
30	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. <i>Science Translational Medicine</i> , 2022 , 14, eabi9215	17.5	15
29	Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses. 2022 ,		3
28	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. 2022 ,		2
27	A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum.. <i>PLoS Pathogens</i> , 2022 , 18, e1010409	7.6	0
26	Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection. 2022 ,		1
25	Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. <i>Cell</i> , 2021 , 184, 6022-6036.e18	56.2	3
24	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. <i>Nature Communications</i> , 2021 , 12, 6055	17.4	56
23	Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19 2021 ,		53
22	AI-guided discovery of the invariant host response to viral pandemics 2021 ,		6
21	Adult Stem Cell-derived Complete Lung Organoid Models Emulate Lung Disease in COVID-19 2021 ,		15
20	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes 2021 ,		26
19	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants 2021 ,		6
18	Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. <i>Cell Reports</i> , 2021 , 35, 108940	10.6	28
17	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>Nature Communications</i> , 2021 , 12, 2938	17.4	110
16	AI-guided discovery of the invariant host response to viral pandemics. <i>EBioMedicine</i> , 2021 , 68, 103390	8.8	13
15	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. <i>Nature Communications</i> , 2021 , 12, 3309	17.4	25
14	Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model. <i>ACS Infectious Diseases</i> , 2021 , 7, 2229-2237	5.5	1

13	Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19. <i>ELife</i> , 2021 , 10,	8.9	18
12	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj5413	17.5	18
11	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , 2020 , 369, 956-963	33.3	906
10	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 2020 ,		35
9	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 2020 ,		40
8	Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections. <i>Viruses</i> , 2020 , 12,	6.2	3
7	Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. <i>Nature Communications</i> , 2018 , 9, 1624	17.4	50
6	Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. <i>Nature Protocols</i> , 2017 , 12, 1261-1276	18.8	529
5	Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	69
4	Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. <i>Science Immunology</i> , 2017 , 2,	28	68
3	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19		10
2	Machine Learning Models Identify Inhibitors of SARS-CoV-2		6
1	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4